Table 1 Baseline clinical characteristics between LDL-C target achievers and non-achievers

Age (yrs) (Mean ± SD)

57.2 ± 13.1

56.1 ± 15.0

58.0 ± 11.5

[Median (IQR)]

59.0 (48.0, 66.0)

58.0 (47.0, 69.0)

59.0 (50.0, 66.0)

Sex (male)

152

(72.0)

65

(71.4)

87

(72.5)

BMI (kg/m²) (Mean ± SD)

26.4 ± 4.1

27.4 ± 4.5

25.8 ± 3.7

[Median (IQR)]

26.2 (23.8, 28.4)

27.0 (24.6, 29.4)

25.4 (23.2, 28.2)

Hypertension

126

(59.7)

51

(56.0)

75

(62.5)

Diabetes mellitus

73

(34.6)

35

(38.5)

38

(31.7)

Smoker

54

(25.6)

21

(23.1)

33

(27.5)

HFrEF

18

(8.5)

7

(7.7)

11

(9.2)

Coronary artery disease

126

(59.7)

48

(52.8)

78

(65.0)

Myocardial infarction

72

(34.1)

23

(25.3)

49

(40.8)

Peripheral artery disease

10

(4.7)

5

(5.5)

5

(4.2)

Ischemic stroke or TIA

13

(6.2)

5

(5.5)

8

(6.7)

CKD without dialysis

25

(11.8)

9

(9.9)

16

(13.3)

ESRD under dialysis

4

(1.9)

1

(1.1)

3

(2.5)

COPD

5

(2.4)

3

(3.3)

2

(1.7)

Liver cirrhosis

2

(1.0)

0

(0.0)

2

(1.7)

Cancer

11

(5.2)

2

(2.2)

9

(7.5)

Anti-platelet drugs

181

(85.8)

72

(79.1)

109

(90.8)

Beta blocker

102

(48.3)

40

(44.0)

62

(51.7)

RAS inhibitor

91

(43.1)

32

(35.2)

59

(49.2)

Non HIS

77

(36.5)

34

(37.4)

43

(35.8)

HIS

14

(6.6)

6

(6.6)

8

(6.7)

Non HIS + Ezetimibe

48

(22.8)

26

(28.6)

22

(18.3)

HIS + Ezetimibe

72

(34.1)

25

(27.5)

47

(39.2)

Alirocumab

155

(73.5)

73

(80.2)

82

(68.3)

Evolocumab

56

(26.5)

18

(19.8)

38

(31.7)